Abstract
The withdrawal of the selective cyclooxygenase 2 inhibitor rofecoxib owing to cardiovascular side effects ignited debate about the need for major changes to current mechanisms for post-marketing surveillance (PMS) of drug safety. Here, we discuss the current mechanisms, whether they are being used appropriately, and consider the need for changes to regulatory systems.
This is a preview of subscription content, log in via an institution to check access.
References
Fitzgerald, G. A. Coxibs and cardiovascular disease. N. Engl. J. Med. 351, 1709–1711 (2004).
Topol, E. J. Failing public health — rofecoxib, Merck and the FDA. N. Engl. J. Med. 351, 1707–1709 (2004).
Frantz, S. How to avoid another 'Vioxx'. Nature Rev. Drug Discov. 4, 5–7 (2005).
Belton, K. J. and the European Pharmacovigilance Research Group Attitude survey of adverse drug reaction reporting by health care professionals across the European Union. Eur. J. Clin. Pharmacol. 6, 423–427 (1997).
Mann, R. D. Prescription Event Monitoring — recent progress and future horizons. Br. J. Clin. Pharmacol. 46, 195–201 (1998).
Safety Assessment of Marketed Medicines. Guidelines for company sponsored safety assessment of marketed medicines. (London MCA, 1993).
Griffin, M. R., Stein, M. S. & Ray, W. A. Post marketing surveillance for drug safety; surely we can do better. Clin. Pharmacol. Ther. 75, 491–494 (2004)
Report of the Committee on Safety of Medicines Expert Working Group on the Safety of Selective Serotonin Reuptake Inhibitor Antidepressants (The Stationery Office, London, 45, 2004).
Jick, H., Kaye, J. & Jick, S. Antidepressants and the risk of suicidal behaviours. JAMA 292, 338–343 (2004)
Glaxo SmithKline. Report quoted in the Committee on Safety of Medicines Expert Working Group on the Safety of Selective Serotonin Reuptake Inhibitor Antidepressants (The Stationery Office, London, 103–104, 2004).
Martinez, C. et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case control study. Br. Med. J. 330, 389 (2005).
Bresalier, R. S. et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352, 1092–1102 (2005).
Rubenstein, S. How best to monitor drugs after they're FDA approved. Q&A Wall Street Journal (20 Dec 2004).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Rights and permissions
About this article
Cite this article
Breckenridge, A., Woods, K. & Raine, J. Monitoring the safety of licensed medicines. Nat Rev Drug Discov 4, 541–543 (2005). https://doi.org/10.1038/nrd1778
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd1778
- Springer Nature Limited
This article is cited by
-
Predicting the frequencies of drug side effects
Nature Communications (2020)
-
Beyond debacle and debate: developing solutions in drug safety
Nature Reviews Drug Discovery (2009)